Salmeterol xinafoate/Tiotropium Bromide Hydrate

昔萘酸沙美特罗/噻托溴铵

Report date: 2022/06/27 20:00:35

Base Information

Drug NameSalmeterol xinafoate/Tiotropium Bromide Hydrate
Drug Alias NameTiotropium bromide/salmeterol噻托溴铵/昔萘酸沙美特罗Salmeterol/tiotropium bromideTiotropium Bromide Hydrate/Salmeterol xinafoate
ClassificationSmall molecules
Mechanisms of ActionBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor M3 antagonists
TargetsBeta-2 adrenergic receptorMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Tiotropium BromideSalmeterol xinafoate
Global Highest StatusDiscontinued (IND)
Highest Status in ChinaDiscontinued
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International GmbhMelep (Beijing) Pharmaceutical Research Co Ltd
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A